LynxBio’s cytomics-based platform technology, MicroC3™, rapidly measures the therapeutic response of patients’ own blood cancer cells to drugs. MicroC3™ seamlessly integrates into the clinical workflow and provides physicians with actionable results within 72 hours of a standard-of-care biopsy.
